

ASTRAZENECA PLC  
Form 6-K  
February 03, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of February 2016

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

AstraZeneca PLC Full-Year and Q4 Results 2015

## Edgar Filing: ASTRAZENECA PLC - Form 6-K

On Thursday, 4 February 2016, AstraZeneca PLC will release its full-year and Q4 2015 results at 07:00 GMT.

A presentation will take place at 12:00 GMT (07:00 EST, 13:00 CET) and will be accessible via two routes:

### Audio webcast

The slides will be available to download via <http://www.astrazeneca.com/investors> prior to the start of the presentation.

### Teleconference

|                     |                  |
|---------------------|------------------|
| UK (freephone):     | 0800 376 922     |
| US (toll-free):     | 1 866 966 1396   |
| Sweden (freephone): | 0207 92102       |
| International:      | +44 20 7192 8000 |

Conference ID: 22241252

Details of the teleconference and webcast replay facilities are available via <http://www.astrazeneca.com/investors>.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 03 February 2016

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary